Press release
Pheochromocytomas and Paragangliomas (PPGL) Market to Set Phenomenal Growth From 2025 to 2034
Pheochromocytomas and Paragangliomas (PPGL) Market
Introduction
Pheochromocytomas and paragangliomas (collectively known as PPGL or PCPG) are rare neuroendocrine tumors that originate from chromaffin cells in the adrenal medulla or extra-adrenal paraganglia. While pheochromocytomas arise in the adrenal glands, paragangliomas occur in various parts of the body including the abdomen, chest, and head-and-neck region.
Although rare, these tumors can be life-threatening if untreated, often associated with excessive catecholamine secretion leading to severe hypertension and cardiovascular complications. Advances in genetic testing, imaging technologies, and targeted therapies have revolutionized early diagnosis and treatment. Growing awareness of hereditary PPGL syndromes and expanded screening protocols are also contributing to a more proactive market landscape.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71616
Market Overview
The global pheochromocytomas and paragangliomas (PCPG) market was valued at USD 670 million in 2024 and is projected to reach USD 1.45 billion by 2034, growing at a CAGR of 8.0% during the forecast period.
Key Highlights:
• Rising recognition of PPGL through genetic testing and improved diagnostic protocols.
• Expanding treatment pipeline including targeted radiopharmaceuticals and kinase inhibitors.
• Increased research funding and orphan drug incentives for rare cancers.
• High unmet medical need in low- and middle-income countries due to limited awareness.
Segmentation Analysis
By Treatment Type
• Surgery (adrenalectomy, tumor resection)
• Chemotherapy
• Targeted therapy (tyrosine kinase inhibitors, radiopharmaceuticals)
• Immunotherapy
• Others (palliative care, combination regimens)
By Drug Class
• Alpha-blockers
• Beta-blockers
• Tyrosine kinase inhibitors
• Radiopharmaceutical agents (e.g., 131I-MIBG, Lutetium-177 therapies)
• Others
By Route of Administration
• Oral
• Intravenous
• Others
By End-User
• Hospitals
• Specialty cancer centers
• Research institutes
• Ambulatory care settings
By Application
• Hereditary PPGL syndromes
• Sporadic PPGL cases
• Recurrent/metastatic PPGL
Segmentation Summary:
Surgery remains the first-line treatment, especially for localized tumors, but targeted therapies and radiopharmaceuticals are gaining momentum for advanced and metastatic cases. Hospitals dominate the end-user segment, though specialty cancer centers are key players in genetic screening, precision oncology, and clinical trials.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71616/pheochromocytomas-and-paragangliomas-pcpg-market
Regional Analysis
North America
• Largest market share due to advanced diagnostics, high awareness, and strong oncology infrastructure.
• The U.S. leads with FDA approvals of targeted radiopharmaceutical therapies for metastatic PPGL.
Europe
• Significant share driven by national rare disease programs and favorable reimbursement for orphan drugs.
• Germany, France, and the UK are leading contributors.
Asia-Pacific
• Fastest-growing region with increasing cancer incidence, expanding healthcare investments, and wider access to genetic screening.
• China, India, and Japan are emerging as major hubs for both treatment adoption and clinical trial activity.
Middle East & Africa
• Smaller share but improving through government-led healthcare reforms and partnerships with global pharma companies.
Latin America
• Brazil and Mexico are at the forefront, supported by expanding cancer care infrastructure and collaborations with international healthcare organizations.
Regional Summary:
North America and Europe dominate the current market, but Asia-Pacific will post the highest CAGR through 2034, driven by population size, improving healthcare access, and adoption of precision oncology.
Market Dynamics
Key Growth Drivers
• Improved genetic testing enabling earlier PPGL diagnosis.
• Advances in imaging technologies such as PET and MRI improving tumor localization.
• Expanding drug pipeline with radiopharmaceuticals and tyrosine kinase inhibitors.
• Orphan drug incentives stimulating investment in rare tumor research.
Key Challenges
• High treatment costs and limited affordability in emerging economies.
• Small patient pool complicating clinical trial recruitment.
• Limited awareness among general practitioners leading to underdiagnosis.
Latest Trends
• Radiopharmaceuticals (e.g., Lutetium-177 DOTATATE) gaining traction as effective targeted therapies.
• Expansion of real-world evidence (RWE) studies to optimize PPGL treatment strategies.
• Precision medicine approaches integrating genomics for hereditary PPGL syndromes.
• Growing collaborations between academic centers and pharmaceutical companies to accelerate research.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71616
Competitor Analysis
Leading Market Players
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• AstraZeneca Plc
• Advanced Accelerator Applications (a Novartis company)
• Ipsen Biopharmaceuticals
• Exelixis, Inc.
• Progenics Pharmaceuticals, Inc.
Competitive Summary:
The PCPG market is moderately consolidated, with major pharmaceutical companies focusing on radiopharmaceuticals, kinase inhibitors, and immunotherapies. Novartis is a front-runner with radioligand therapies, while biotech firms are developing innovative targeted drugs for metastatic PPGL. Strategic alliances, orphan drug designations, and accelerated approval pathways are shaping the competitive dynamics.
Conclusion
The global pheochromocytomas and paragangliomas (PCPG) market is expected to grow from USD 670 million in 2024 to USD 1.45 billion by 2034, expanding at a robust CAGR of 8.0%.
Key Takeaways:
• North America and Europe dominate, but Asia-Pacific will grow fastest due to expanding healthcare access.
• Surgery remains the cornerstone of treatment, but radiopharmaceuticals and targeted therapies are driving innovation.
• Orphan drug policies and regulatory incentives are accelerating drug development.
• Challenges include high treatment costs, small patient populations, and limited awareness in developing regions.
This report is also available in the following languages : Japanese (褐色細胞腫および傍神経節腫(PCPG)市場), Korean (갈색세포종 및 부신신경종(PCPG) 시장), Chinese (嗜铬细胞瘤和副神经节瘤(PCPG)市场), French (Marché des phéochromocytomes et des paragangliomes (PCPG)), German (Markt für Phäochromozytome und Paragangliome (PCPG)), and Italian (Mercato dei feocromocitomi e dei paragangliomi (PCPG)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71616
Our More Reports:
Genotoxicity Testing Market
https://exactitudeconsultancy.com/reports/72432/genotoxicity-testing-market
RNA Therapeutics Fundamental Analysis Market
https://exactitudeconsultancy.com/reports/72431/rna-therapeutics-fundamental-analysis-market
EZH2 Inhibitors Market
https://exactitudeconsultancy.com/reports/72430/ezh2-inhibitors-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pheochromocytomas and Paragangliomas (PPGL) Market to Set Phenomenal Growth From 2025 to 2034 here
News-ID: 4173776 • Views: …
More Releases from Exactitude Consultancy
Esophageal Cancer Patient Pool Analysis Market Insights and Future Outlook
Introduction
Esophageal cancer is one of the most lethal gastrointestinal malignancies, ranking among the top ten causes of cancer-related deaths globally. The disease is primarily classified into two subtypes: squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). Both subtypes have distinct geographical prevalence patterns, risk factors, and treatment responses, creating a complex and evolving market landscape.
The esophageal cancer patient pool analysis market plays a vital role in understanding treatment demand, patient demographics,…
Automated Compounding Devices Market is expected to reach USD 2.3 billion by 203 …
Automated compounding devices (ACDs) have become essential in modern healthcare systems, particularly in hospital pharmacies and oncology centers. These devices are designed to prepare sterile, accurate, and customized doses of intravenous (IV) medications, including chemotherapy drugs, parenteral nutrition, and high-risk injectable therapies. By reducing manual intervention, ACDs significantly improve safety, precision, and efficiency, minimizing the risk of dosing errors and contamination.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71627
The…
Anaplastic Large Cell Lymphoma (ALCL) Market New Product Development & Latest Tr …
Introduction
Anaplastic large cell lymphoma (ALCL) is a rare and aggressive subtype of non-Hodgkin's lymphoma (NHL) that arises from T-cells. ALCL accounts for a small proportion of lymphomas but is clinically significant due to its aggressive nature and the availability of unique therapeutic pathways, such as targeting the anaplastic lymphoma kinase (ALK) protein in ALK-positive cases.
Over the past decade, major breakthroughs in targeted therapies, monoclonal antibodies, and immunotherapy have transformed the…
Sezary Syndrome (SS) Market 2025-2034 Business Outlook, Critical Insight and Gro …
Introduction
Sezary syndrome (SS) is a rare and aggressive form of cutaneous T-cell lymphoma (CTCL), characterized by the presence of malignant T-lymphocytes in the blood, skin, and lymph nodes. Patients often present with erythroderma, lymphadenopathy, and circulating atypical cells, making management complex. Due to its rarity and poor prognosis, SS represents a significant unmet need in oncology.
In recent years, advances in targeted therapies, monoclonal antibodies, and immunomodulators have provided new hope…
More Releases for PPGL
Pheochromocytomas and Paragangliomas Market
Introduction
Pheochromocytomas and Paragangliomas (PPGLs) are rare neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla (pheochromocytomas) or extra-adrenal ganglia (paragangliomas). These tumors often produce excess catecholamines, leading to hypertension, palpitations, headaches, and cardiovascular complications. While typically benign, a subset may become malignant, significantly complicating patient management.
Historically, PPGLs have been underdiagnosed due to their nonspecific symptoms, but advances in genetic testing, imaging, and biochemical assays have improved detection. With…
Rising Tumor Incidence Rates Fueling Growth In The Pheochromocytoma Market Drivi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Pheochromocytoma Market Size By 2025?
The market size of pheochromocytoma has been on a steady upward trend over the past years. It is projected to increase from $3.03 billion in 2024 to $3.17 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 4.7%.…
Top Factor Driving Pheochromocytoma Market Growth in 2025: Rising Tumor Incidenc …
How Big Is the Pheochromocytoma Market Expected to Be, and What Will Its Growth Rate Be?
The pheochromocytoma market has grown steadily in recent years. It will rise from $3.03 billion in 2024 to $3.17 billion in 2025, at a CAGR of 4.7%. This growth is attributed to increased healthcare spending, a rise in diagnoses and awareness, genetic research, and government initiatives.
The pheochromocytoma market is projected to see steady growth, reaching…
Thickness of color coated plate and how to pick the color of color coated coil
Color coated plate [https://www.ehongsteel.com/ppgippgl-color-coated-steel-coil-factory-manufacture-color-coated-prepainted-steel-coil-product/] PPGI/PPGL is a combination of steel plate and paint, so is its thickness based on the thickness of the steel plate or on the thickness of the finished product?First of all, let's understand the structure of color coated plate for construction:
Image: https://www.ehongsteel.com/uploads/PPGI-Layer.jpg
(Image source: Internet)
There are two ways to express the thickness of PPGI [https://www.ehongsteel.com/low-price-color-coated-steel-coil-ppgi-ppgl-china-supplier-color-steel-coil-product/]/PPGL [https://www.ehongsteel.com/ppgippgl-color-coated-steel-coil-factory-manufacture-color-coated-prepainted-steel-coil-product/]
First, the finished thickness of color coated plateFor example: finished thickness of…
Pheochromocytoma Market Growth, Analysis And Forecast 2033
The new report published by The Business Research Company, titled Pheochromocytoma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the pheochromocytoma market size has grown steadily in recent years. It will grow from $2.89 billion in 2023 to $3.03…
Pheochromocytoma Market Growth Rate, Latest Trends, Industry Insights And Foreca …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Pheochromocytoma Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.56 billion In 2028 At A…
